David B Duggan

Summary

Affiliation: SUNY Upstate Medical University
Country: USA

Publications

  1. ncbi request reprint Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
    David B Duggan
    Department of Medicine, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    J Clin Oncol 21:607-14. 2003
  2. ncbi request reprint Every error a treasure: improving medication use with a nonpunitive reporting system
    David F Lehmann
    Department of Medicine, State University of New York Upstate Medical Universtiy, Syracuse, New York, USA
    Jt Comm J Qual Patient Saf 33:401-7. 2007
  3. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
    David B Duggan
    Department of Medicine, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    J Clin Oncol 21:607-14. 2003
    ..We compared these regimens as initial chemotherapy for Hodgkin's disease...
  2. ncbi request reprint Every error a treasure: improving medication use with a nonpunitive reporting system
    David F Lehmann
    Department of Medicine, State University of New York Upstate Medical Universtiy, Syracuse, New York, USA
    Jt Comm J Qual Patient Saf 33:401-7. 2007
    ..The revised medication event reporting policy, as established in October 2000 for all staff, severed the link between reporting errors and performance evaluations...
  3. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...